AZTR news

Azitra adjusted the protocol of its topical ATR-04-484 Phase 1/2 study to include patients treating rash caused by KRAS and MEK inhibitors, widening the potential patient pool beyond those on EGFR inhibitors.

Ex vivo testing of ATR-COSF demonstrated significant wrinkle reduction and elasticity improvement, with findings to be presented at BIO-Europe in November.

Azitra filed to amend its charter to implement a 10-for-1 reverse stock split, set to occur on October 26, 2026. This corporate action aims to stabilize the price of its common stock.

Azitra announced the completion of Cohort 1 and clearance for Cohort 2 of a clinical trial evaluating drug candidate ATR04-484 as a treatment for EGFR inhibitor-induced skin rash, following a safety review. The advancement marks a significant milestone for the company's live biotherapeutic program a…

Azitra Inc. announced a sales agreement with A.G.P./Alliance Global Partners for periodic sales of its common stock. This allows the company to sell shares to raise capital over time.

Azitra will present at the H.C. Wainwright investment conference, highlighting pipeline updates including ATR-04 and the ATR-COSF program for cosmetic applications.

Azitra, Inc. has been notified by NYSE American that it has resolved continued listing deficiencies under Sections 1003(a)(ii) and 1003(a)(iii) and will no longer carry the '.BC' indicator. The company maintains a focus on its clinical development pipeline and adherence to listing requirements.

Azitra announced positive ex vivo results demonstrating increased penetration and anti-wrinkle efficacy for its filaggrin cosmetics program. These results indicate potential validation of the safety profile and commercial potential of their cosmetic division.

CEO Francisco Salva outlined strategic reorientation initiatives following a $10.5M financing in March, expanding beyond precision dermatology into cosmetic ingredients and biotech tools. The company aims to leverage microbial genetic engineering technology to participate in larger markets with shor…

Azitra increased total authorized shares from an unstated prior amount to 760M shares, comprising 750M common shares and 10M preferred shares. The amendment provides greater flexibility for future equity issuances and capital structure management.

Azitra's 2026 Annual Meeting was adjourned from June 4 to June 15 because only 17% of shares were represented, below the required 33.3% quorum threshold. The reconvened virtual meeting allows additional time for stockholder participation and voting on company proposals.

Azitra announced it will convene its 2026 annual stockholder meeting on June 4, 2026, then immediately adjourn and reconvene on June 15, 2026, citing a minor administrative delay in mailing proxy materials. The postponement allows additional time for stockholders to receive and submit proxy material…